Our quantitative SARS-CoV-2 antibody assay can help clinicians establish a baseline to evaluate an individual's antibody immune response. Our access SARS-CoV-2 IgG (1st IS) is traceable to the 1 st WHO International Standard for anti-SARS-CoV-2.
What are the indications for serological testing for SARS-CoV-2 (COVID-19)?
Testing patients who may have had COVID-19 or exposure to it, more than 14 days ago.
Return to work as prescribed by the state and local Public Health Departments in their most up -to-date recommendations.
Serological testing is NOT indicated for diagnosis of acute infection.
How are the results reported, and what is the clinical significance?
The results are either "reactive" or "non-reactive" based on the manufacture-indicated cutoff. An antibody activity (titer) will also be reported.
A non-reactive result indicates that either a person has not been infected with COVID-19 or there is not a detectable level of antibody present. A non-reactive result does not rule out current or past infection with COVID-19.
A reactive result indicates previous or current infection. It is important to note that a reactive serology test cannot distinguish between active or past COVID-19. If there is concern for active infection, molecular testing(PCR) with a nasopharyngeal swab is recommended.
At this time, it is not known how long the antibody response lasts, or the association between antibody response and clinical outcomes of individuals with COVID-19.
It is possible you might est reactive for antibodies and you might not have or have ever had symptoms of COVID-19. This is known as having an asymptomatic infection, or an infection without symptoms.
What are the limitations of this test?
This is not intended for acute diagnosis early in the course of the disease. As stated above, non-reactive results do not rule out a COVID-19 is high, PCR-based testing is recommended to evaluate infection. Antibody testing should not be used alone to diagnose COVID-19.
False-positive results rarely may occur as the result of infection with non-COVID-19 human coronaviruses.
Immunocompromised patients with COVID-19 may not have detectable levels of antibodies or may have a delayed antibody response.